Nevertheless, most Ras/ERK signaling molecules are often overexpressed in breast cancer [12], suggesting that there are other genomic and/or epigenetic regulations involved in the aberrant activation of the Ras/ERK pathway [5, 7, 13]. This evidence concerns the gene MAPK1 and breast carcinoma.